Novo Nordisk A/S is following in rival Eli Lilly & Co.’s footsteps by selling its hit weight-loss drug Wegovy directly to US patients at a discount.

Some commercially insured patients stand to save $150 per month on Wegovy, a popular obesity medication. Patients on Medicare and Medicaid are not eligible.

The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly diving into the opportunity to make anti-obesity products. This article looks into key players in the arena.

A U.S. federal judge has refused to allow compounding pharmacies to keep making copies of Eli Lilly's popular weight-loss and diabetes drugs Zepbound and Mounjaro in the United States.

Minnesota lawmakers are renewing a push to require insurance coverage of anti-obesity drugs like Ozempic and Wegovy. Why it matters: These life-changing drugs, known as GLP-1s, are helping millions of Americans shed pounds and lower their risk of more serious conditions like heart attacks and strokes.

Novo Nordisk said it would drop prices by 25 percent for all doses of the drug, making the new monthly price about $500.

US taxpayers spent an estimated $6 billion researching, developing, and implementing new blockbuster weight-loss drugs, according to new data shared with the Lever. Yet Americans are now paying pharmaceutical giants — including one in Denmark — up to eleven times more for these medicines than patients in other countries,